Featured Research

from universities, journals, and other organizations

Anti-tumor Effects Are Enhanced By Inhibiting Two Pathways Rather Than One

Date:
August 25, 2008
Source:
Journal of Clinical Investigation
Summary:
Two independent research groups have found that simultaneous inhibition of two signaling pathways -- mTOR and MAPK signaling pathways -- results in substantially enhanced antitumor effects when compared with inhibition of either pathway alone in mouse models of prostate and breast cancer.

Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that still need to be answered.

In the first study, Pier Paolo Pandolfi and colleagues, at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, and Memorial Sloan-Kettering Cancer Center, New York, report that tumor samples from patients with biopsy-accessible solid tumors of advanced disease treated with a drug that inhibits the mTOR signaling pathway showed increased activation of the MAPK signaling pathway. Similar results were observed in a mouse model of prostate cancer following treatment with the same drug.

As inhibition of the MAPK signaling pathway enhanced the antitumoral effects of inhibition of the mTOR signaling pathway in mice transplanted with a human breast cancer cell line, the authors suggest that a combination therapy using drugs that target each pathway might improve the treatment of human cancers.

In the second study, Cory Abate-Shen and colleagues, at Columbia University College of Physicians and Surgeons, New York, and the University of Medicine & Dentistry of New Jersey, Piscataway, show that simultaneous inhibition of the mTOR and MAPK signaling pathways inhibited the in vitro growth of prostate cancer cell lines and the in vivo growth of prostate tumors in a mouse model of prostate cancer. This was particularly true in a model of highly aggressive and frequently lethal forms of the disease, which do not respond to hormone deprivation therapy, leading the authors to suggest that this combination therapy might be particularly useful for treating patients with advanced, hormone-refractory prostate cancer.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal References:

  1. Carracedo et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation, 2008; DOI: 10.1172/JCI34739
  2. Kinkade et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. Journal of Clinical Investigation, 2008; DOI: 10.1172/JCI34764

Cite This Page:

Journal of Clinical Investigation. "Anti-tumor Effects Are Enhanced By Inhibiting Two Pathways Rather Than One." ScienceDaily. ScienceDaily, 25 August 2008. <www.sciencedaily.com/releases/2008/08/080821194709.htm>.
Journal of Clinical Investigation. (2008, August 25). Anti-tumor Effects Are Enhanced By Inhibiting Two Pathways Rather Than One. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2008/08/080821194709.htm
Journal of Clinical Investigation. "Anti-tumor Effects Are Enhanced By Inhibiting Two Pathways Rather Than One." ScienceDaily. www.sciencedaily.com/releases/2008/08/080821194709.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins